Oncolytics Biotech (ONCY) Retained Earnings (2009 - 2026)
Oncolytics Biotech (ONCY) posted quarterly Retained Earnings of $6.2 million for Q4 2025, up 804.89% year-over-year from $687931.0 in Q4 2024, and up 985.79% quarter-over-quarter from $573315.0 in Q3 2025.
Oncolytics Biotech (ONCY) Retained Earnings (2009 - 2026) Analysis & Trends
Oncolytics Biotech (ONCY) has reported Retained Earnings for 17 consecutive years, with $6.2 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Retained Earnings rose 804.89% year-over-year to $6.2 million; the TTM figure through Dec 2025 stood at $6.2 million (up 804.89% YoY), while the FY2025 annual figure was $6.2 million, up 101.55% from the prior year.
- Retained Earnings advanced to $6.2 million in Q4 2025 per ONCY's latest filing, from $573315.0 in the prior quarter.
- Across five years, Retained Earnings topped out at $6.2 million in Q4 2025 and bottomed at $253448.7 in Q2 2021.
- Historically, Retained Earnings has averaged $740007.4 across 5 years, with a median of $487578.6 in 2022.
- Annual changes were most pronounced in 2021 — Retained Earnings plunged 62.55% — and 2025, when it jumped 804.89%.
- Oncolytics Biotech's Retained Earnings stood at $307814.4 in 2021, then surged by 58.44% to $487697.3 in 2022, then slipped by 18.07% to $399587.3 in 2023, then soared by 72.16% to $687931.0 in 2024, then surged by 804.89% to $6.2 million in 2025.
- Business Quant data shows ONCY's Retained Earnings at $6.2 million in Q4 2025, $573315.0 in Q3 2025, and $519633.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.24 Bn | 131.39 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 86.01 Bn | 78.02 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 65.61 Bn | 60.42 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 56.92 Bn | 51.78 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.27 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 27.77 Bn | 9.38 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.52 Bn | 26.36 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - | 4.38 Bn |
| 10 | Oncolytics Biotech | 98.20 Mn | 98.20 Mn | - | -448.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -448.18 Mn |
| Dec 31, 2025 | 6.23 Mn |
| Sep 30, 2025 | 573,315.02 |
| Jun 30, 2025 | 519,633.00 |
| Mar 31, 2025 | 667,645.98 |
| Dec 31, 2024 | 687,931.02 |
| Sep 30, 2024 | 478,683.88 |
| Jun 30, 2024 | 527,883.48 |
| Mar 31, 2024 | 497,215.85 |
| Dec 31, 2023 | 399,587.33 |
| Sep 30, 2023 | 488,584.46 |
| Jun 30, 2023 | 412,426.67 |
| Mar 31, 2023 | 487,459.90 |
| Dec 31, 2022 | 487,697.35 |
| Sep 30, 2022 | 554,074.61 |
| Jun 30, 2022 | 355,495.34 |
| Mar 31, 2022 | 268,996.38 |
| Dec 31, 2021 | 307,814.40 |
| Sep 30, 2021 | 322,887.66 |
| Jun 30, 2021 | 253,448.69 |